{"analyses":[{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","estimateComment":"IPTW HR were estimated using weighted Cox proportional hazard models and confidence intervals were estimated using robust error variances. Stabilized IPT weights truncated at the 99.5th percentile were used.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"=0.0182","paramType":"Hazard Ratio (HR)","paramValue":"0.68","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.56","upperLimit":"10.41","value":"6.87"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"6.64","value":"5.32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"238"}],"units":"Participants"}],"description":"TTD: a) C1071003 Cohort A: time from the date of first dose of elranatamab to discontinuation. Participants were censored at death, loss to or end of follow-up. B) Flatiron Health Database: time from initiation of the SOC to discontinuation (end) of the SOC. Participants were censored at loss to follow-up, death, or end of the study period. Kaplan Meier method was used for analysis. Retrospective data was evaluated in this observational study for approximately 9 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible participants with TCR-MM, who were BCMA naïve, who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) Cohort A were included.","id":"OG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR-MM who initiated SOC treatment and were identified from Flatiron Health database in real world setting under routine clinical practice outside of clinical trials were included. This arm served as external control arm.","id":"OG001","title":"RWD: Flatiron Health Database"}],"paramType":"MEDIAN","populationDescription":"Eligible participants whose data was retrieved and was used in this retrospective cohort study. In this outcome measure, IPTW analysis was applied. IPTW eliminated the effect of confounding by observed baseline participant characteristics, improve covariate balance, and thereby obtained unbiased estimates of treatment effects.","reportingStatus":"POSTED","timeFrame":"C1071003: Date of first dose to discontinuation or censoring whichever occurred first (maximum of 2.09Y); Flatiron Health Database: SOC to discontinuation of SOC or censoring whichever occurred first (maximum of 6.45Y)","title":"TTD: C1071003 Cohort A Versus Flatiron Health Database Using IPTW Analysis","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}